The 2026 Peptide Tier List: S/A/B/C Rankings

Tier lists are inherently subjective — and that's the point. Peptide science is full of noise: overhyped compounds with zero human data sitting next to genuinely revolutionary molecules that most people have never heard of. We built this ranking to cut through it.

Our criteria: evidence quality (human > animal > anecdotal), safety profile (established vs. unknown), regulatory accessibility in 2026, consumer demand, and practical real-world utility. Peptides that score high across all five land in S-Tier. Peptides that score high in only one or two land lower.

Every peptide that has its own WellSourced guide is linked directly — this article is designed to be your hub for the entire peptide landscape.

📋 Medical Disclaimer: This article is for informational purposes only. No peptide mentioned is FDA-approved for the indications discussed (unless specifically noted). Do not use this as medical advice. Consult a licensed healthcare provider before starting any peptide protocol.

How We Ranked

Each tier represents a specific evidence-and-utility profile:

S-Tier: Exceptional evidence base OR proven clinical track record + favorable safety + high accessibility in 2026
A-Tier: Strong evidence or strong clinical momentum; one or two significant caveats
B-Tier: Promising early-stage data, niche use cases, or excellent evidence in a narrow domain
C-Tier: Overhyped, under-researched, high-risk, or poor risk/reward relative to alternatives

Regulatory status changed dramatically in 2026. BPC-157, TB-500, and 11 other peptides were removed from the FDA's Category 2 restricted list in April 2026, which meaningfully shifts their accessibility scores. We've factored this in.

The 2026 Peptide Tier List

Best-in-class — evidence, safety, and real-world utility all align

BPC-157 — Body Protection Compound

The most researched healing peptide in this tier list by a significant margin. Over 700 peer-reviewed studies document its mechanisms across tendon, gut, joint, and nerve tissue. As of April 2026, it's off the FDA's Category 2 list, making it more accessible than at any point in the past five years. The evidence-to-safety ratio here is exceptional — extensive animal data showing robust therapeutic effects with no meaningful toxicity signals, plus growing real-world use in regenerative medicine clinics. Full BPC-157 guide →

⚡ Verdict: S-Tier across gut healing, tendon/ligament repair, and anti-inflammatory applications.

Why some would rank it lower BPC-157 still lacks Phase 3 human RCTs. The evidence is compelling but almost entirely preclinical. We rank it S-Tier because the mechanistic data is exceptional and clinical adoption is accelerating — but acknowledge this is not proven to FDA drug-approval standards.

GHK-Cu — Copper Peptide

GHK-Cu sits in an unusual position: it has strong human data (relatively rare in peptide science), a decades-long safety record through topical cosmetic use, and a remarkable mechanism that touches collagen synthesis, wound healing, anti-inflammatory signaling, and even gene expression. Dr. Loren Pickart's research documented 4,000+ gene interactions. It's the only peptide on this list with legitimate clinical evidence in both dermatology and wound healing. The barrier to entry is low — topical application requires no needles. Full GHK-Cu guide →

⚡ Verdict: S-Tier for skin health and wound healing. Potentially A-Tier for systemic applications where injectable evidence is thinner.

Semaglutide — GLP-1 Receptor Agonist

Semaglutide is the only peptide on this list with full FDA approval, robust Phase 3 trial data, and prescribable access through mainstream medicine. Ozempic (diabetes) and Wegovy (obesity) have fundamentally changed how we approach metabolic disease. The cardiovascular data from SUSTAIN and SELECT trials is remarkable: 20% reduction in major cardiovascular events. This is S-Tier on evidence — it's not a question. The caveats (muscle loss risk, compounding bans) keep it from dominating the list, but as a peptide it's in a category of one. Semaglutide deep-dive → | Compounded Semaglutide in 2026 →

⚡ Verdict: S-Tier on evidence. Some users trade down due to side effects or prefer Tirzepatide/Retatrutide — but the data here is unmatched in this space.

The muscle loss concern The 2025 SURMOUNT-4 analysis flagged that ~40% of weight lost on semaglutide was lean mass. This is real and important. We still rank it S-Tier because the cardiovascular and metabolic benefits are extraordinarily well-documented — but users should stack resistance training and consider adequate protein. GLP-1 muscle loss study breakdown →

Strong performers — one or two significant caveats keep them from S

TB-500 — Thymosin Beta-4 Fragment

TB-500 is the canonical complement to BPC-157. Where BPC-157 drives angiogenesis and gut healing, TB-500 excels at cell migration, actin remodeling, and connective tissue flexibility. The "Wolverine Stack" (BPC-157 + TB-500) has become the standard protocol for serious musculoskeletal injuries in the regenerative medicine community — and the mechanistic rationale for why these two complement each other is solid. TB-500 also exited the FDA Category 2 list in April 2026. What keeps it out of S-Tier: the evidence base is smaller than BPC-157, and the dosing is less intuitive (2–5mg twice weekly vs. daily mcg dosing). Full TB-500 guide →

⚡ Verdict: A-Tier solo, potential S-Tier performance when stacked with BPC-157 for connective tissue injuries.

Semax — Synthetic ACTH Fragment

Semax is Russia's most-studied nootropic peptide — developed by the Russian Academy of Sciences, it has undergone multiple human clinical trials for cognitive enhancement, neuroprotection after stroke, and ADHD. The evidence base is real, peer-reviewed, and includes human data. It's been prescribed in Russia and Ukraine for decades. The caveats: all major trials were conducted in Russian academic institutions, which creates replication concerns, and regulatory access in the US is limited. It's the closest thing the nootropic world has to a legitimate clinical-grade cognitive enhancer. Full Semax guide → | Semax vs Selank →

⚡ Verdict: A-Tier for cognitive applications. The Russian human trial data is real — but verification outside that system remains limited.

MOTS-c — Mitochondrial Peptide

MOTS-c is encoded in mitochondrial DNA, not nuclear DNA — which makes it biologically unique on this list. It mimics the metabolic effects of exercise: it improves insulin sensitivity, drives fatty acid oxidation, and appears to enhance physical performance. Human pilot data published in 2023–2025 is promising. What keeps it from S-Tier: it's still early-stage in humans, dosing protocols are not yet standardized, and its effects on aging (which look extraordinary in mice) haven't been replicated in long-term human trials. The upside here is enormous if the human data holds. Full MOTS-c guide →

⚡ Verdict: A-Tier now, possible S-Tier in 3–5 years if the human longevity data holds.

Retatrutide — Triple GIP/GLP-1/Glucagon Agonist

Retatrutide is the most exciting metabolic peptide in active development. Phase 2 data showed 24% body weight reduction at 48 weeks — beating semaglutide and tirzepatide in head-to-head context. If Phase 3 results hold, this becomes the dominant weight-loss peptide of the 2020s. We rank it A-Tier because it's not yet approved and Phase 3 is still ongoing. Placing an unapproved Phase 3 compound in S-Tier would be premature — but we'd be dishonest if we didn't acknowledge the extraordinary momentum here. Full Retatrutide guide →

⚡ Verdict: A-Tier in 2026. Expected S-Tier candidate upon approval (projected 2027–2028).

Why we didn't rank it S-Tier Phase 2 data can look extraordinary; Phase 3 frequently disappoints. We've seen enough promising metabolic drugs fail in late trials that we maintain appropriate skepticism. Retatrutide earns its A ranking entirely on the strength of Phase 2 results.

Thymosin Alpha-1 — Immune Modulator

Thymosin Alpha-1 is approved in 37 countries (sold as Zadaxin) for hepatitis B, hepatitis C, and adjuvant cancer therapy. The human evidence base is substantial. In 2020, it attracted significant attention for COVID-19 treatment in Italian clinical trials. Its immune-modulating effects — it works like a "dimmer switch" on immune response, upregulating when immune function is low and downregulating when overactive — are well-documented. In the US it's only accessible through compounding, which creates friction, but the underlying science is A-Tier by any measure. Full Thymosin Alpha-1 guide →

⚡ Verdict: A-Tier. Globally approved, solid human data, niche but clinically meaningful.

Promising — strong in narrow domains or early-stage but credible

Epithalon — Telomere Peptide

Epithalon (Epitalon) has the most interesting longevity data of any peptide in the B-Tier. Russian researchers at the St. Petersburg Institute of Bioregulation documented 42% lifespan extension in mice — and reported that cancer incidence in treated animals dropped significantly. Human studies exist but are small and not independently replicated. Epithalon activates telomerase, the enzyme that maintains telomere length, which is the closest any compound has come to targeting biological aging at the cellular foundation. B-Tier because the human data needs replication. If you're interested in longevity, it deserves serious attention. Full Epithalon guide →

⚡ Verdict: B-Tier on current evidence. The longevity thesis is compelling enough to watch closely.

PT-141 (Bremelanotide / Vyleesi) — Sexual Health

PT-141 is the only FDA-approved peptide on this list specifically for sexual dysfunction — Vyleesi is approved for hypoactive sexual desire disorder (HSDD) in premenopausal women. That's real regulatory validation. The challenge: it works centrally (in the brain, not through the vascular system like Viagra), which produces different effects and different side effects (nausea, flushing, transient blood pressure increases). It's genuinely effective for its indication. B-Tier because the indication is narrow and off-label use is poorly studied. Full PT-141 guide →

⚡ Verdict: B-Tier overall, but S-Tier within its approved indication for appropriate candidates.

Selank — Anxiolytic Nootropic

Selank is the anxiolytic counterpart to Semax — developed by the same Russian institution, with clinical trials demonstrating anti-anxiety effects comparable to phenazepam (benzodiazepine) without the addiction risk or sedation. The mechanism (GABA modulation + BDNF upregulation) is well-characterized. The challenge is the same as Semax: Russian clinical data, limited independent replication, and poor US regulatory accessibility. B-Tier for now — worth watching as Western researchers replicate the findings. Semax vs Selank comparison →

⚡ Verdict: B-Tier. Credible but geographically siloed evidence base.

SS-31 (Elamipretide) — Mitochondrial Peptide

SS-31 targets the inner mitochondrial membrane — specifically cardiolipin, a phospholipid that is essential for electron transport chain function. As mitochondrial dysfunction underlies virtually every age-related disease, a peptide that directly improves mitochondrial function has enormous theoretical upside. Phase 2 data in heart failure (Stealth BioTherapeutics) showed signals. The challenge: the company went bankrupt, leaving the clinical program in limbo. The biology is compelling; the clinical development is incomplete. B-Tier because the science deserves respect even without Phase 3 data. Full SS-31 guide →

⚡ Verdict: B-Tier. The mitochondrial mechanism is legitimate — the clinical program is stalled.

Tirzepatide — Dual GIP/GLP-1 Agonist

Tirzepatide (Mounjaro for diabetes, Zepbound for obesity) is FDA-approved and showed 22% body weight reduction in the SURMOUNT-1 trial. It's the current gold standard for GLP-1 therapy available today. The reason it's not in S-Tier: we're being precise. Semaglutide has a longer evidence history and broader regulatory footprint. Tirzepatide is A-tier-adjacent but lands in B-tier here because the long-term outcomes data (cardiovascular, all-cause mortality) is still maturing. In clinical terms, Tirzepatide is excellent — the ranking reflects evidence age, not quality. The GLP-1 evolution →

⚡ Verdict: Strong B-Tier, borderline A. Excellent peptide — the long-term data just isn't as deep as semaglutide's yet.

Proceed with caution — overhyped, under-researched, or poor risk/reward

AOD-9604 — HGH Fragment

AOD-9604 was supposed to be the fat-burning fragment of HGH with none of the downsides. The trials didn't cooperate. Four Phase 2 clinical trials failed to show statistically significant weight loss over placebo. Metabolex went bankrupt. The compound technically received Generally Recognized as Safe (GRAS) approval for use in food from the FDA in 2014, which the supplement industry has enthusiastically misrepresented as clinical efficacy evidence. It's not. C-Tier because the human trials were done and they were negative. AOD-9604 full breakdown →

⚡ Verdict: C-Tier. Ran Phase 2 trials. Lost. Move on.

Why some still use it Anecdotal reports of mild fat-loss benefits persist, and some researchers speculate the oral trials failed due to poor bioavailability. Injectable AOD-9604 remains popular in some circles. We're unconvinced — when a compound runs four trials and all four are negative, that's data.

Follistatin — Myostatin Inhibitor

Follistatin inhibits myostatin, which limits muscle growth. The theory is straightforward: block myostatin → remove the governor on muscle development → dramatic muscle growth. The problem: Follistatin-344 (the peptide commonly circulating in bodybuilding circles) is not follistatin. It's a truncated form that doesn't properly inhibit myostatin and has raised safety concerns in animal models related to cancer promotion. The legitimate follistatin research is in gene therapy, not peptide administration. C-Tier for the version that's actually being sold and used.

⚡ Verdict: C-Tier. The mechanism is interesting; the compound in circulation is a safety concern.

Kisspeptin — Reproductive Hormone Signaling

Kisspeptin plays a legitimate role in reproductive endocrinology — it's the master regulator of GnRH (gonadotropin-releasing hormone) pulsatility. In clinical settings, it's used for IVF trigger protocols. The problem is off-label use in bodybuilding as a testosterone booster, which has no meaningful evidence base in healthy males. One small study showed acute LH/testosterone response after single-dose administration; long-term effects on the HPG axis in healthy individuals are unknown and potentially concerning. C-Tier for off-label use in the general population.

⚡ Verdict: C-Tier for off-label use. Legitimate in clinical reproductive medicine.

CJC-1295 / Ipamorelin (Alone) — GHRH/Ghrelin Analogues

CJC-1295 and Ipamorelin stimulate growth hormone release. Individually, the evidence for meaningful body composition changes or anti-aging benefits in healthy adults is weak. They work — they do raise GH pulse amplitude — but the clinical significance of that GH elevation in non-deficient adults is contested. When used as part of a comprehensive healing stack alongside BPC-157, they may contribute to the overall effect. As standalone compounds marketed for fat loss, muscle gain, or anti-aging in healthy individuals, the evidence-to-hype ratio is poor. C-Tier on standalone merits; useful as adjuncts.

⚡ Verdict: C-Tier standalone. Potentially useful additions to a BPC-157 + TB-500 healing protocol.

Why this placement is contested Many regenerative medicine clinics prescribe GHRH + ghrelin mimetic combinations as first-line protocols. The clinical experience is positive. We remain skeptical that the benefit-to-risk ratio justifies widespread use in healthy adults without clear GH deficiency — especially with long-term HPG axis effects understudied.

The 2026 Regulatory Landscape — Context for Rankings

Rankings don't exist in a vacuum. The April 2026 FDA decision to remove BPC-157, TB-500, and 11 other peptides from the Category 2 restricted list fundamentally changed the accessibility calculus. Peptides that were gray-market compounds six months ago are now available through compounding pharmacies with a prescription.

This matters for rankings: accessibility is a real component of utility. A peptide with excellent evidence that you can't access isn't practically useful. The 2026 regulatory thaw has moved several compounds from "theoretical option" to "clinically prescribable option."

The July 2026 PCAC hearing — where the FDA's advisory panel will evaluate BPC-157, Semax, Epitalon, and four others for permanent inclusion on the 503A bulk drug substances list — will be another inflection point. We'll update this tier list after the panel's recommendations are published. Full PCAC hearing preview →

How to Use This Tier List

Tier lists are starting points, not protocols. A C-Tier peptide may be exactly right for a specific clinical indication that a S-Tier peptide doesn't address. Context matters.

Practical framework:

Musculoskeletal injuries (tendon, ligament, muscle): Start with the BPC-157 + TB-500 stack. Both are now compoundable and have the best evidence-to-risk ratio in this category.
Gut health: BPC-157 alone (oral). The evidence is specific and strong. No stack needed to start.
Weight loss / metabolic: Semaglutide or Tirzepatide through a licensed provider. If Phase 3 is positive, Retatrutide will likely displace both.
Longevity / anti-aging: GHK-Cu (topical) is the lowest-risk, highest-evidence starting point. MOTS-c and Epithalon are worth monitoring.
Cognitive function: Semax if you can access it through a reputable source. Limited options in this category with real evidence.

What's Not on This List (And Why)

We deliberately excluded several compounds that generate significant search traffic but don't meet our minimum evidence threshold:

Peptide YY, Oxytocin, Vasopressin: Legitimate neuropeptides with interesting research, but off-label administration protocols have insufficient safety data.
Collagen peptides (oral): The evidence for hydrolyzed collagen is real but modest. It's more supplement than peptide therapy.
Melanotan II: Not included due to significant safety concerns (uncontrolled melanocyte activation, cardiovascular risks reported).
GHK-Cu + DHT combination formulas: The specific DHT component raises androgenic concerns that warrant exclusion from a general ranking.

AI-Discovered Peptides to Watch

A new category is emerging that doesn't fit cleanly into the existing S/A/B/C framework: peptides discovered or designed using artificial intelligence and machine learning. These aren't conventional compounds that happened to be studied with AI tools — they are novel molecular structures that wouldn't exist without generative AI.

Honest framing first: most AI-discovered peptides are pre-clinical or in early Phase 1. The pipeline is real and accelerating, but clinical proof is thin. We're watching this space because the design-to-candidate timelines are collapsing — what used to take years of combinatorial chemistry now happens in weeks. That compression will matter.

🤖 Why This Matters Traditional peptide drug discovery is slow. Synthesizing and testing thousands of variants by hand takes years. AI changes the math: tools like RFdiffusion (Baker Lab, UW) and Insilico's Biology42 engine can generate and screen thousands of novel peptide structures computationally in days, then synthesize only the top candidates for wet-lab validation. RFpeptides — published in Nature Chemical Biology (June 2025) — achieved a 76% hit rate on novel macrocyclic peptides against previously difficult protein targets. Insilico generated 5,000 novel GLP-1R peptides in 72 hours, with 14 showing biological activity and 3 reaching single-digit nanomolar potency. The pipeline from "design" to "testable candidate" has collapsed from years to weeks. The practical question isn't whether AI will accelerate peptide development — it already has. The question is which AI-designed candidates will survive Phase 2 and 3.

AI WATCH

Novel compounds designed or identified by AI — pre-clinical to early clinical | Evidence: emerging

RFpeptides Macrocycles — Baker Lab / UW Institute for Protein Design Pre-Clinical

The Baker Lab's RFpeptides framework (published Nature Chemical Biology, June 2025) designs ring-shaped macrocyclic peptides from scratch using diffusion AI — the same class of generative models behind modern image generation, adapted for molecular structure. The results are notable: 76% of tested designs showed biological activity against four diverse target proteins. The best candidate against GABARAP bound with a KD of 6 nM — comparable to antibody-class binders, in a much smaller molecule format. Macrocycles are uniquely interesting because they can reach intracellular targets that conventional peptides can't, and they are more stable (resistant to enzymatic degradation). The UW has licensed the technology to Vilya, an IPD spinout. No human trials yet — this is a platform, not a single compound. Watch the targets that come out of it.

⚡ Evidence grade: Pre-clinical (in vitro validation, no animal or human data). Monitor for: first IND filing from Vilya. Why it matters: proves AI can design functional peptide binders de novo, not just optimize existing ones.

Important caveat RFpeptides is a design platform — it produces candidate scaffolds. The actual therapeutic value depends entirely on which targets are pursued and whether the candidates survive the full development process. In vitro binding affinity ≠ clinical efficacy. The 76% hit rate is impressive for design; the clinical attrition rate for all peptides (AI-designed or not) remains brutal.

AI-Designed GLP-1 Receptor Agonists — Novel Long-Acting Variants Pre-Clinical

Multiple independent groups have now used AI to design entirely novel GLP-1 receptor agonist peptides — not semaglutide analogues, but structurally distinct molecules. The most notable 2025 result: candidates D13 and D41 (generated via ProteinMPNN + molecular dynamics screening from 10,000 AI-designed variants) showed half-lives approximately 3× longer than semaglutide in animal models, with lower blood glucose in diabetic mice. ImmunoPrecise Antibodies separately reported AI-designed GLP-1 peptides surpassing semaglutide in receptor activation studies. Insilico Medicine's Biology42 engine designed 5,000 novel GLP-1R peptides in 72 hours, identifying candidates with single-digit nanomolar potency. None of these are in human trials yet. The significance: AI is not just optimizing existing GLP-1 scaffolds — it's designing new structural solutions to the same receptor target, potentially with better half-lives and side effect profiles.

⚡ Evidence grade: Pre-clinical (animal data; no human trials). Monitor for: IND filings and Phase 1 initiation. Why it matters: semaglutide and tirzepatide may eventually be succeeded by AI-native GLP-1 designs with superior pharmacokinetics.

Rentosertib (ISM001-055) — Insilico Medicine TNIK Inhibitor Phase 2a ✓

Rentosertib is technically a small molecule, not a peptide — but it belongs in this section because it is the most clinically advanced compound ever discovered entirely by a generative AI system, and its progression tells us something important about the pipeline. Insilico's end-to-end AI platform identified rentosertib as a TNIK inhibitor for idiopathic pulmonary fibrosis from scratch. The Phase 2a results were published in Nature Medicine (August 2025): 71 patients randomized, signals across multiple dosing arms. First AI-discovered drug to reach Phase 2. It's not a peptide. But it's the proof that the AI → clinical candidate → trial pathway works at all — and Insilico is now applying the same platform to peptide-based therapeutics (including their GLP-1R candidates above).

⚡ Evidence grade: Phase 2a human data (published, Nature Medicine 2025). Why it matters: establishes that generative AI drug discovery produces compounds that work in humans, not just in silico.

PepTune — Multi-Property Optimized Therapeutic Peptides Pre-Clinical

PepTune (2025) introduces a different AI approach: instead of designing a peptide for a single property (binding affinity), it simultaneously optimizes for five properties — binding affinity, solubility, membrane permeability, hemolysis risk, and anti-fouling characteristics. The tool uses a masked diffusion language model guided by Monte Carlo Tree Guidance. The significance is practical: most peptides fail not because they don't bind their target, but because they're insoluble, impermeable, or toxic. Multi-property AI optimization attacks the attrition problem from the design stage rather than the formulation stage. No specific therapeutics from PepTune are in clinical development yet — this is a design methodology that multiple groups will apply to their programs.

⚡ Evidence grade: Computational / pre-clinical. Monitor for: first therapeutics designed with PepTune or equivalent multi-objective AI to enter trials. Why it matters: addresses the biggest failure modes of peptide drugs at the design stage.

Grading note: AI-Watch entries are not ranked S/A/B/C. Most are too early-stage for evidence-tier placement. We grade each on clinical maturity (Pre-Clinical / Phase 1 / Phase 2) and will migrate candidates into the main tiers as human data accumulates. The contrast with S-Tier compounds like BPC-157 (700+ studies, 25+ years of data) and Semaglutide (multiple Phase 3 RCTs, FDA approval) is intentional — it's a reminder of how much runway AI-discovered peptides still have to cover.

FAQ — Peptide Tier List 2026

What is the best peptide in 2026?

For healing and tissue repair, BPC-157 has the best evidence-to-risk ratio. For metabolic health and weight loss, Semaglutide has the most established clinical evidence. The "best" peptide is context-dependent — there's no universal answer.

Is BPC-157 really S-Tier?

We rank it S-Tier based on the breadth of mechanistic evidence (700+ studies), the diversity of applications (gut, tendons, joints, nerves), and the exceptional safety profile across all animal data. We acknowledge it lacks Phase 3 human RCT data — that's the honest caveat. If you require FDA drug-approval level evidence as your standard, then BPC-157 belongs in A-Tier.

Why is Tirzepatide not in S-Tier?

Tirzepatide is excellent. It's in B-Tier not because of quality concerns but because semaglutide has a longer evidence track record, broader cardiovascular outcomes data (the SELECT trial), and deeper long-term safety data. Tirzepatide's long-term outcomes data is still maturing. In clinical terms, the difference is marginal.

What happened to AOD-9604?

AOD-9604 ran four Phase 2 clinical trials for fat loss. All four failed to beat placebo. It has the highest trial-to-evidence-failure ratio of any compound in this tier list. That's C-Tier by definition.

Are there any AI-designed peptides available?

Not in clinical use yet — but the pipeline is real and moving fast. As of 2026, the most advanced AI-designed therapeutic is rentosertib (Insilico Medicine), a small molecule that completed Phase 2a trials published in Nature Medicine. On the peptide side specifically, Baker Lab's RFpeptides platform has demonstrated 76% hit rates designing novel macrocyclic peptides de novo, and multiple groups have AI-designed GLP-1 receptor agonists showing 3× longer half-lives than semaglutide in animal models. None are FDA-approved or in Phase 3 yet. See the AI-Discovered Peptides to Watch section above for detailed coverage of what's in the pipeline and how to evaluate maturity.

Where can I learn more about each peptide?

Every S-Tier and A-Tier peptide has a dedicated WellSourced guide. The links are embedded throughout this article. For a full overview of the peptide landscape, start with our Peptides 101 beginner's guide.